Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
The Safety and Efficacy of Stem Cell Therapy for Diabetic Peripheral Neuropathy in Animal Studies: A Systematic Review and Meta-Analysis
36 Pages Posted: 2 May 2024
More...Abstract
Background: Diabetes mellitus results in end-organ injury such as diabetic neuropathy which has a significant impact on patients' quality of life. The present study aimed to evaluate the safety and efficacy of utilizing stem cell therapy for diabetic peripheral neuropathy (DPN).
Methods: A systematic search of MEDLINE, Embase, Scopus, the Web of Science, and the Cochrane Central Register of Controlled Trials was performed. The time period was from inception to January 31, 2024, with no language restrictions. All animal studies investigating the efficacy and safety of stem cell therapy for treating DPN were included. A random-effects model to combine effect sizes in our meta-analysis was applied.
Findings: 29 out of the 5431 records met the eligibility criteria. In these studies, stem cell therapy improved motor and sensory nerve conduction velocity, compound muscle action potential (CMAP), and sciatic nerve blood flow. Post-treatment, mechanical and thermal nociceptive thresholds decreased. Rats had significant improvement in axonal circularity, nerve growth factor, and transforming growth factor beta 1; mice had significant increased in weight, CMAP, and angiopoietin 1. The stem cell subgroup study showed that dental pulp stem cells had the greatest effects across all parameters, while bone marrow mononuclear cells had strong biochemical responses.
Interpretation: Stem cell therapy demonstrates promising efficacy in ameliorating neuropathic symptoms in DPN animal models. Human patient studies and targeted treatment procedures for specific neuropathic disorders are advocated to improve therapeutic outcomes.
Funding: This work was funded by the Tehran University of Medical Sciences with grant number of 1402-1-93-65474.
Declaration of Interest: The authors declare that they have no competing interests.
Ethical Approval: he Ethics Committee of Tehran University of Medical Sciences approved the study, and the reference number is IR.TUMS.SINAHOSPITAL.REC.1402.052.
Keywords: Diabetic Neuropathy, Stem Cell Transplantation, Animal Model, Meta-Analysis
Suggested Citation: Suggested Citation